Aldosterone and progression of kidney disease.
- Published in:
- Therapeutic Advances in Cardiovascular Disease, 2009, v. 3, n. 2, p. 133, doi. 10.1177/1753944708100409
- By:
- Publication type:
- Article
Works matching IS 17539447 AND DT 2009 AND VI 3 AND IP 2
Results: 7
1
2
Memorial.
- Published in:
- Therapeutic Advances in Cardiovascular Disease, 2009, v. 3, n. 2, p. 101, doi. 10.1177/1753944709102830
- By:
- Publication type:
- Article
3
Effects of enalapril, candesartan or both on neurohumoral activation and LV volumes and function in patients with heart failure not treated with a beta-blocker.
- Published in:
- Therapeutic Advances in Cardiovascular Disease, 2009, v. 3, n. 2, p. 113, doi. 10.1177/1753944708103658
- By:
- Publication type:
- Article
4
Blood pressure responder rates versus goal rates: which metric matters?
- Published in:
- Therapeutic Advances in Cardiovascular Disease, 2009, v. 3, n. 2, p. 157, doi. 10.1177/1753944708101552
- By:
- Publication type:
- Article
5
Advances in the prevention of sudden cardiac death in the young.
- Published in:
- Therapeutic Advances in Cardiovascular Disease, 2009, v. 3, n. 2, p. 145, doi. 10.1177/1753944708100181
- By:
- Publication type:
- Article
6
Hyperaldosteronism in pregnancy.
- Published in:
- Therapeutic Advances in Cardiovascular Disease, 2009, v. 3, n. 2, p. 123, doi. 10.1177/1753944708100180
- By:
- Publication type:
- Article
7
Olmesartan improves left ventricular function in pressure-overload hypertrophied rat heart by blocking angiotensin II receptor with synergic effects of upregulation of angiotensin converting enzyme 2.
- Published in:
- Therapeutic Advances in Cardiovascular Disease, 2009, v. 3, n. 2, p. 103, doi. 10.1177/1753944708098691
- By:
- Publication type:
- Article